Ligand Pharmaceuticals Inc. Announces Market Launch of Bazedoxifene in Japan and Spain for the Treatment of Postmenopausal Osteoporosis

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Pfizer, Inc. (NYSE:PFE) launched Viviant® (Bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis. Under the brand name Conbriza®, the drug is also marketed in Spain through a co-promotion with Almirall, an international pharmaceutical company based in Spain. Pfizer received manufacturing and marketing approval for the product in Japan in July 2010. Viviant was approved in April 2009 by the European Commission (under the trade name Conbriza®) for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.

Back to news